Home › Myelodysplastic Syndromes › Washington
Myelodysplastic Syndromes clinical trials in Washington
21 studies for Myelodysplastic Syndromes are looking for participants at sites in Washington.
Cities in Washington
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06577441A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Fred Hutchinson Cancer Center, Seattle
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Washington, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- and 1 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06529731Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Jul 22, 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT07046078Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Up to age 80 · All sexes · Updated May 18, 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT06928662A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Mar 12, 2026 · NCT03970096HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 2
3 Months · All sexes · Updated Nov 12, 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.